Type 1 cytokine response and treatment outcome of genital HPV lesions.

Genitourinary Medicine Pub Date : 1997-10-01 DOI:10.1136/sti.73.5.387

G Stellato, P Nieminen, M Aho, T Lehtinen, M Lehtinen, J Paavonen

{"title":"Type 1 cytokine response and treatment outcome of genital HPV lesions.","authors":"G Stellato, P Nieminen, M Aho, T Lehtinen, M Lehtinen, J Paavonen","doi":"10.1136/sti.73.5.387","DOIUrl":null,"url":null,"abstract":"Objectives: To determine the role of type 1 cytokines as predictors of response to treatment of genital HPV lesions with laser ablation with or without adjuvant systemic interferon alpha 2b (IFN-alpha).Methods: Measurement of serum interleukin 2 (IL-2), IL-2 soluble receptor alpha (sIL-2 alpha), interferon gamma, and human papilloma virus (HPV) DNA in patients undergoing treatment of genital HPV lesions with carbon dioxide laser and systemic IFN-alpha. A randomised, placebo controlled study of 92 cases with 6 months of follow up.Results: High IL-2/sIL-2 alpha was associated with 60% to 70% protection against recurrences both in the IFN-alpha and placebo groups (OR = 0.4, 90%, CI 0.1-2.5; OR = 0.3, 90% CI 0.0-1.8, respectively). Diagnostic phase serum IL-2 predicted favourable outcome (OR = 0.2, 90% CI 0.0-1.0) in women with high load of HPV DNA or HPV 16/18 DNA regardless of the adjuvant therapy.Conclusions: Serum IL-2 determinations may identify women with good prognosis following laser ablation of genital HPV lesions.","PeriodicalId":12621,"journal":{"name":"Genitourinary Medicine","volume":"73 5","pages":"387-90"},"PeriodicalIF":0.0000,"publicationDate":"1997-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/sti.73.5.387","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genitourinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/sti.73.5.387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Objectives: To determine the role of type 1 cytokines as predictors of response to treatment of genital HPV lesions with laser ablation with or without adjuvant systemic interferon alpha 2b (IFN-alpha).

Methods: Measurement of serum interleukin 2 (IL-2), IL-2 soluble receptor alpha (sIL-2 alpha), interferon gamma, and human papilloma virus (HPV) DNA in patients undergoing treatment of genital HPV lesions with carbon dioxide laser and systemic IFN-alpha. A randomised, placebo controlled study of 92 cases with 6 months of follow up.

Results: High IL-2/sIL-2 alpha was associated with 60% to 70% protection against recurrences both in the IFN-alpha and placebo groups (OR = 0.4, 90%, CI 0.1-2.5; OR = 0.3, 90% CI 0.0-1.8, respectively). Diagnostic phase serum IL-2 predicted favourable outcome (OR = 0.2, 90% CI 0.0-1.0) in women with high load of HPV DNA or HPV 16/18 DNA regardless of the adjuvant therapy.

Conclusions: Serum IL-2 determinations may identify women with good prognosis following laser ablation of genital HPV lesions.

查看原文本刊更多论文

生殖器HPV病变的1型细胞因子反应和治疗结果。

目的:确定1型细胞因子作为预测激光消融治疗生殖器HPV病变反应的作用，辅助或不辅助系统性干扰素2b (ifn - α)。方法:在接受二氧化碳激光和全身ifn - α治疗生殖器HPV病变的患者中，测定血清白细胞介素2 (IL-2)、IL-2可溶性受体α (sIL-2 α)、干扰素γ和人乳头瘤病毒(HPV) DNA。92例随机对照安慰剂研究，随访6个月。结果:在ifn - α组和安慰剂组中，高IL-2/sIL-2 α与60% - 70%的复发保护相关(OR = 0.4, 90%， CI 0.1-2.5;OR = 0.3, 90% CI分别为0.0-1.8)。无论辅助治疗如何，诊断期血清IL-2预测HPV DNA或HPV 16/18 DNA高负荷妇女的有利结果(OR = 0.2, 90% CI 0.0-1.0)。结论:血清IL-2检测可以鉴别出生殖器HPV病变激光消融后预后良好的女性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genitourinary Medicine

自引率

0.00%

发文量